The Israeli government has approved the export of medicinal cannabis



[ad_1]

About a month ago, a law regulating the conditions for the export of cannabis for medical purposes was adopted in the Knesset (Israeli Parliament), the Israeli government has approved a decision to make exports effective to countries where their use is permitted.

According to Israeli government estimates, the global market for medicinal cannabis reaches around $ 27,000 million a year. Israel's export potential would be over one billion US dollars.

The decision was made after the Ministry of Finance and the Ministry of Homeland Security decided to increase the police budget to enable it to oversee this region and the production of cannabis for medical purposes in Israel.

Israeli Finance Minister Moshe Kahlon said about the approval: "I have totally supported the export of medicinal cannabis and I congratulate this decision. The export of cannabis for medical purposes will give Israel a considerable advantage in the relationship between research and development, agriculture and the cannabis industry, generating significant revenues for the country."

Kahlon added: "Farmers, industrial factories and distributors have already made big investments because of their intentions and they can now benefit from their efforts."

Next year, between April 1st and April 3rd, Tel Aviv will participate in an exclusive conference on cannabis science and technology: Cannatech Tel Aviv 2019.

Israel is known to be one of the leading centers for the development of cannabis-related technologies and is considered the world leader in medical research on cannabis. According to one of the organizers of CannaTech there are more than 100 clinical trials in Israel on cannabis in more than 30,000 patients, something unprecedented worldwide.

Some Israeli companies have already made progress in areas related to medical cannabis. For example, InterCure, chaired by Israeli Prime Minister Ehud Barak, managed to secure a $ 17 million fund to strengthen its activities.

[ad_2]
Source link